Fosamax (Alendronate) in Your 40s: What Every Woman in Perimenopause Should Know About Her Bones

Why Bone Loss in Your 40s Is a Women's Health Issue, Not a "Later" Problem

Bone loss in perimenopause begins earlier than most women expect. The average age of the final menstrual period in the United States is 51, but bone density can start declining as early as the late 30s to early 40s, well before periods become irregular. The drop accelerates steeply in the two to three years surrounding the final menstrual period, when estrogen withdrawal drives osteoclast activity to outpace bone formation.

A landmark analysis published in the New England Journal of Medicine found that women lose an average of 10-12% of lumbar spine bone mass in the five-year window surrounding menopause, a rate that far exceeds the roughly 1% per year seen in the decades before and after that window. For women in their 40s who are already perimenopausal, this means bone loss is happening now, not in some abstract future.

What "Perimenopause" Actually Means for Your Skeleton

The hormonal transition of perimenopause is not a single event. Estrogen levels fluctuate unpredictably for months to years before the final menstrual period. During those fluctuations, bone remodeling markers (serum CTX, P1NP) can spike significantly higher than in premenopausal women, reflecting increased bone turnover even when you still have periods. This means a woman in her mid-40s with irregular cycles may already be losing bone at a rate that matters clinically.

The Gap Between Bone Loss and Diagnosis

Most women have no symptoms from declining bone density. A 2020 CDC analysis found that fewer than 25% of women aged 45-54 who met criteria for low bone mass had ever had a DEXA scan. By the time a fragility fracture occurs, significant bone capital has already been spent. The practical consequence: do not wait for a broken wrist or a hip X-ray to prompt the first bone conversation with your clinician.

What Is Alendronate and How Does It Work?

Alendronate is a bisphosphonate, a class of drugs that binds to hydroxyapatite on bone surfaces and inhibits osteoclast-mediated resorption. Unlike estrogen, it does not replace a hormone. It slows the rate at which old bone is removed, shifting the remodeling balance in favor of net bone gain.

The drug is absorbed poorly from the gut (bioavailability roughly 0.6% of the oral dose under ideal conditions) and must be taken on an empty stomach with a full 8-ounce (240 mL) glass of plain water, at least 30 minutes before any food, drink, or other medication. FDA prescribing information for alendronate specifies remaining upright (sitting or standing) for at least 30 minutes after ingestion to reduce esophageal irritation risk.

Dosing Forms Relevant to Women in Their 40s

| Indication | Dose | Frequency | |---|---|---| | Treatment of osteoporosis (postmenopausal) | 10 mg daily or 70 mg | Daily or once weekly | | Prevention of postmenopausal osteoporosis | 5 mg daily or 35 mg | Daily or once weekly | | Premenopausal osteoporosis (off-label) | 70 mg | Once weekly | | Glucocorticoid-induced osteoporosis | 5 mg daily (35 mg/week if postmenopausal) | Daily or once weekly |

The 70 mg once-weekly tablet is by far the most prescribed formulation because weekly dosing shows equivalent efficacy to daily dosing with better gastrointestinal tolerability in head-to-head data.

Should You Actually Take Fosamax in Your 40s?

For the large majority of women in their 40s, the answer is not yet. Alendronate has strong evidence for reducing fracture risk in women with established osteoporosis or prior fragility fracture, but the evidence for starting it in perimenopausal women without osteoporosis is much thinner.

When Alendronate Might Be Appropriate in Your 40s

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on osteoporosis identifies the following scenarios where pharmacologic treatment is warranted regardless of menopausal status:

• A T-score at or below -2.5 at the lumbar spine, total hip, or femoral neck (meeting the WHO definition of osteoporosis).
• A prior low-trauma (fragility) fracture of the hip or spine.
• A T-score between -1.0 and -2.5 (osteopenia) combined with a 10-year FRAX major osteoporotic fracture probability at or above 20%, or a hip fracture probability at or above 3%.

Secondary osteoporosis also matters. Women in their 40s who have been on long-term glucocorticoids, have a history of anorexia nervosa, have undergone premature ovarian insufficiency (POI), or have conditions causing malabsorption (celiac disease, inflammatory bowel disease) may meet treatment thresholds years before age 50.

When Alendronate Is Likely Not the Right Call Yet

If your DEXA scan shows osteopenia (T-score between -1.0 and -2.5) and your FRAX probability is below the treatment threshold, the evidence does not support starting a bisphosphonate in your 40s. In that scenario, the Menopause Society (formerly NAMS) 2023 position statement on hormone therapy supports menopausal hormone therapy as a first-line option for bone preservation in symptomatic perimenopausal women, with bone protection as a secondary benefit.

For women in their 40s who are not candidates for or do not want hormone therapy, optimization of calcium (1,000-1,200 mg/day from diet plus supplement), vitamin D (maintaining serum 25-OH vitamin D at 30-50 ng/mL), weight-bearing and resistance exercise, and smoking cessation are the recommended first interventions before bisphosphonates enter the picture.

Sex-Specific Physiology: Why the Female Body Responds Differently

Estrogen and the Bone Remodeling Cycle

Estrogen receptors are expressed on both osteoblasts and osteoclasts. Estrogen normally suppresses osteoclast lifespan and activity. As estrogen fluctuates in perimenopause, that suppression becomes inconsistent, and bone turnover markers reflect that instability. This is distinctly different from age-related bone loss in men, which is more gradual and tied to declining testosterone and IGF-1 rather than the abrupt hormonal withdrawal women experience.

Pharmacokinetics in Women Versus Men

Alendronate trials have predominantly enrolled postmenopausal women, so the pharmacokinetic data in premenopausal or perimenopausal women is limited. One pharmacokinetic analysis in the FDA label notes that renal clearance of alendronate does not differ meaningfully by sex when creatinine clearance is accounted for, but body composition differences (women carry proportionally more adipose tissue) do not significantly alter bone-specific bioavailability. The bisphosphonate incorporates directly into bone matrix regardless of sex.

Bone Geometry Matters

Women have, on average, smaller bone cross-sectional area than men at equal BMD values, which means that for a given T-score, a woman's absolute fracture risk may differ from the population used to construct some risk tools. The FRAX algorithm was validated separately by sex, which is why you should always select "female" when calculating your score.

Conditions That Raise the Stakes: PCOS, POI, and Secondary Bone Loss

Several conditions that disproportionately affect women can alter both the timeline and the indication for alendronate in the 40s.

PCOS and Bone Density

Women with PCOS often have higher androgen levels and, in some studies, modestly higher bone density compared to age-matched controls during reproductive years. A 2019 meta-analysis in the Journal of Clinical Endocrinology & Metabolism found that premenopausal women with PCOS had slightly higher lumbar spine BMD than controls, possibly because elevated androgens convert peripherally to estrogen. This does not guarantee protection into perimenopause, particularly in lean women with PCOS who may have had prolonged amenorrhea.

Premature Ovarian Insufficiency

POI (loss of ovarian function before age 40) significantly accelerates bone loss. Women diagnosed with POI in their 30s who are now in their 40s and not on hormone replacement are at meaningfully higher fracture risk. ACOG Committee Opinion 698 recommends hormone therapy until at least the average age of natural menopause (51) in women with POI, with bone densitometry to monitor. Bisphosphonates may be added if BMD continues to decline despite HT or if HT is contraindicated.

Glucocorticoid Use

Women with autoimmune conditions (lupus, rheumatoid arthritis, asthma, inflammatory bowel disease) who have used prednisone 5 mg/day or equivalent for three or more months fall into glucocorticoid-induced osteoporosis risk. The American College of Rheumatology 2022 guideline on glucocorticoid-induced osteoporosis recommends initiating bisphosphonate therapy at lower T-score thresholds in this group, meaning a woman in her 40s on long-term steroids may qualify for alendronate sooner than the general perimenopausal population.

Pregnancy, Lactation, and Contraception: The Mandatory Conversation

Alendronate is contraindicated in pregnancy. This is not a soft contraindication. Bisphosphonates incorporate into bone matrix and are released slowly over years. Animal studies show skeletal and other fetal abnormalities at doses producing systemic exposure equivalent to human doses. There are no adequate, well-controlled studies in pregnant women, and the drug is classified FDA Pregnancy Category C (older classification) with no adequate human safety data.

Why This Matters Acutely in Your 40s

Women in their 40s can and do become pregnant. Perimenopause is not infertility. Ovulation continues to occur, sometimes unpredictably, until the final menstrual period is confirmed (defined as 12 months of amenorrhea). A 44-year-old woman with irregular cycles may still conceive.

Before prescribing alendronate to any woman of reproductive age, your clinician should:

1. Confirm you are not currently pregnant (urine or serum hCG).
2. Discuss reliable contraception for the duration of treatment and a defined period afterward.
3. Document a shared understanding of the teratogenic risk.

The "Skeletal Reservoir" Problem

Alendronate is not excreted quickly. Studies have detected bisphosphonate in urine for years after the last dose, reflecting slow release from bone. This means conception shortly after stopping alendronate still carries theoretical fetal exposure risk. No specific washout period has been established in guidelines with certainty, but most specialists advise waiting at least six months to one year after stopping before attempting conception, with the understanding that skeletal reservoir exposure is likely impossible to completely eliminate.

Lactation

Alendronate is not recommended during breastfeeding. Bisphosphonate transfer into breast milk is poorly studied in humans. Given the prolonged skeletal retention and theoretical neonatal exposure, most guidelines advise against use in breastfeeding women. The National Institutes of Health LactMed database notes insufficient human data to assess risk, and caution is warranted.

If You Are Trying to Conceive

If you are in your 40s with low bone density and actively trying to conceive, alendronate is not the right tool. Options to discuss with a reproductive endocrinologist and a bone health specialist include calcium and vitamin D optimization, weight-bearing exercise, and whether the underlying cause of bone loss (such as POI or hypothalamic amenorrhea) warrants targeted treatment.

Who This Drug Is Right For, and Who Should Wait

Right for You If:

• You are in perimenopause with a DEXA-confirmed T-score at or below -2.5.
• You have had a low-trauma fracture (wrist after a minor fall, vertebral compression fracture found incidentally).
• Your FRAX score puts your 10-year major fracture risk at or above 20%.
• You are on long-term glucocorticoids and meet the ACR 2022 risk thresholds.
• You have a condition (POI, celiac disease, prior bariatric surgery) driving secondary osteoporosis and HT is not sufficient or not appropriate.
• You are not pregnant, not breastfeeding, and using reliable contraception.

Not Right for You If:

• Your DEXA shows osteopenia and FRAX probability is below treatment thresholds.
• You are pregnant or planning pregnancy in the near term.
• You have significant kidney disease (creatinine clearance <35 mL/min; alendronate is contraindicated in this range per the FDA label).
• You have esophageal abnormalities (stricture, achalasia) that prevent you from remaining upright.
• You have never had a DEXA scan and are working only from clinical suspicion.
• Hormone therapy is a viable option for you and addresses your perimenopausal symptoms alongside bone protection.

Side Effects Women in Their 40s Report Most Often

Most women tolerate alendronate well when dosing instructions are followed precisely. The most common side effects are gastrointestinal:

• Esophageal irritation or ulceration: Risk is substantially reduced by the 30-minute upright rule and taking with a full glass of water. Women with a history of GERD may have a lower tolerance threshold.
• Abdominal discomfort and nausea: More common with daily dosing than weekly; switching to the 70 mg once-weekly formulation often resolves this.
• Musculoskeletal pain: Bone, joint, and muscle pain are listed in the FDA label and can be severe. If severe pain begins after starting alendronate, report it to your clinician promptly.

Rare but Serious: Atypical Femur Fracture and ONJ

Two rare adverse effects receive significant attention:

Atypical femur fracture (AFF): A stress fracture of the femoral shaft with a characteristic radiologic pattern, associated with long-term bisphosphonate use. A large Swedish cohort study estimated the absolute risk at 11 per 100,000 patient-years in women taking bisphosphonates for 1-3 years, rising to 113 per 100,000 patient-years after more than 8 years of use. This risk must be weighed against the fracture risk being prevented. For most women in their 40s starting treatment, the short-term AFF risk is very low.

Osteonecrosis of the jaw (ONJ): Far more common with intravenous bisphosphonates at oncology doses than with oral alendronate. A systematic review in JAMA found ONJ incidence with oral bisphosphonates at approximately 1 in 10,000 to 1 in 100,000 patient-years, predominantly in patients with active dental disease or requiring invasive dental procedures. Inform your dentist you are taking alendronate before any extractions or implant procedures.

Drug Holidays: A Concept That Is Particularly Relevant in Your 40s

If you start alendronate in your 40s and your bone density stabilizes, a drug holiday (planned interruption) after three to five years of therapy may be appropriate. Alendronate's long skeletal half-life means bone protection continues for some time after stopping, and a 2006 JAMA analysis of the FLEX trial found that women who discontinued alendronate after five years maintained significantly better hip BMD than those given placebo at year 10.

A drug holiday is not a permanent stop. It is a period of monitoring, typically with repeat DEXA at 18-24 month intervals, during which treatment is paused and reinitiated if BMD declines or fracture occurs. This strategy is especially relevant for women who start alendronate in their 40s and may otherwise face decades of continuous use.

What to Ask Your Clinician at Your Next Visit

The following framework helps you structure a productive bone health conversation if you are in perimenopause in your 40s:

1. DEXA first. Ask whether you qualify for a DEXA scan under your insurance (most plans cover it at age 65, but earlier coverage applies if you have risk factors). If you pay out of pocket, DEXA costs roughly $100-$250 at many imaging centers.
2. FRAX calculation. Ask your clinician to calculate your 10-year fracture probability using the WHO FRAX tool. Note that FRAX may underestimate risk in women with very low bone turnover or secondary causes.
3. Hormone therapy conversation. If you have perimenopausal symptoms (hot flashes, sleep disruption, vaginal dryness), Menopause Society guidance supports HT as a first-line bone-protective strategy in women under 60 or within 10 years of menopause who have no contraindications.
4. Secondary causes. Ask for thyroid function, calcium, vitamin D, and parathyroid hormone levels if you have risk factors. Untreated hypothyroidism and hyperparathyroidism both accelerate bone loss and are common in women in their 40s.
5. Contraception plan. If alendronate is recommended and you have any possibility of pregnancy, confirm your contraception plan with your clinician before the first dose.

The Evidence Gap: What We Do Not Know About Alendronate in Perimenopausal Women

Women in their 40s are the group most likely to be facing this decision and the group with the least direct evidence to guide it. The landmark bisphosphonate trials, including the Fracture Intervention Trial (FIT), enrolled postmenopausal women and showed a 47% reduction in vertebral fracture risk in women with existing vertebral fractures, and a 51% relative reduction in hip fracture risk in women with low femoral neck BMD. These results are compelling, but the average participant in FIT was in her mid-60s, not her mid-40s.

Extrapolating FIT data to a 46-year-old in early perimenopause requires assumptions that have not been directly tested. The absolute fracture risk at 46 is lower than at 65, which means the absolute benefit of alendronate is also smaller, even if the relative risk reduction is similar. Clinicians and patients in this age group are making decisions with less certainty than the trial data implies, and that uncertainty deserves to be named plainly.

An ACOG 2021 practice bulletin on osteoporosis acknowledges that bisphosphonate data in premenopausal women is limited and that treatment decisions in younger women should be made individually, weighing secondary cause treatment, severity of bone loss, and fracture history.